Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1842295 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $27.63Day +1.32%Mkt cap $1.5B1Y +78.3%Off 52W high −48.5%Vol (1Y) 85.1%
Daily closing price, split-adjusted to the current basis; 1.4y shown of 365 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest10.0% of sh out |
| Days to cover8.5d |
| 13F net flow (QoQ)−2.07% |
| Top-10 13F concentration57.2% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$122.5M |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−33.3% |
| 1Y+78.3% |
| Since incept. (ann.)+44.5% |
Total return through 2026-07-30 · series begins 2025-01-31. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)85.1% |
| Ann. volatility (3Y)92.5% |
| Sharpe (1Y)1.09 |
| Sharpe (3Y)0.86 |
| Max drawdown (1Y)−54.4% |
| Max drawdown (3Y)−54.4% |
| Beta (3Y vs SPY)2.13 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 4.6M | $136M | 8.25% | +0.0% |
| TRV GP IV, LLC | 4.5M | $134M | 8.08% | +0.0% |
| ARCH Venture Management, LLC | 4.1M | $123M | 7.44% | +0.0% |
| Deep Track Capital, LP | 3.5M | $104M | 6.28% | −18.1% |
| JANUS HENDERSON GROUP PLC | 2.9M | $85M | 5.17% | −9.0% |
| Paradigm Biocapital Advisors LP | 2.7M | $82M | 4.96% | new |
| BlackRock, Inc. | 2.6M | $77M | 4.64% | +12.4% |
| a16z Capital Management, L.L.C. | 1.7M | $51M | 3.08% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-12 | −$0.45 | — | $20.0M | — |
| 2025-09-30 | 2025-11-06 | −$0.66 | — | — | — |
| 2025-06-30 | 2025-08-12 | −$0.77 | −123.9% | $0 | −100.0% |
| 2025-03-31 | 2025-05-14 | −$1.15 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 86d) — not company-confirmed.
